Pyxis Oncology(PYXS)

Focus: Pyxis Oncology is a publicly traded biotechnology company focused on antibody immunotherapy for oncology indications. The company is early-stage with minimal revenue and operates at substantial R&D intensity.

Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Pyxis Oncology

AI assessmentNot Hiring

No open roles listed right now. Follow Pyxis Oncology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$16M

Pipeline & Clinical Trials

PYX-201

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT05720117A Study of PYX-201 in Advanced Solid Tumors

Phase 1

Help build intelligence for Pyxis Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with four active programs in Phase 1-2 across high-value oncology indications including melanoma and glioblastoma
Focused expertise in antibody immunotherapy modality offers deep technical specialization for immunology-focused scientists
Publicly traded status (ticker: PYXS) provides liquidity and formal governance structure typical of later-stage biotech

Watch Out For

Severe cash burn with $77M net loss in FY2025 against only $19M cash on hand—runway concerns are acute
Zero revenue growth ($16M flat year-over-year) with no marketed products or commercial infrastructure
No current open positions and minimal pipeline maturity (no Phase 3 programs) means limited near-term career trajectory or job security
R&D intensity of 364% indicates unsustainable unit economics and high probability of restructuring or capital raise pressure

Generated by Claude from Pyxis Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

PYX-106

Solid Tumor

PHASE_1

Clinical Trials (1)

NCT05718557Study of PYX-106 in Solid Tumors

Phase 1

APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

Glioblastoma Multiforme

PHASE_1

Clinical Trials (1)

NCT03389802Phase I Study of APX005M in Pediatric Central Nervous System Tumors

Phase 1

PYX-201

Advanced Solid Tumours

PHASE_1_2

APX005M

Melanoma

PHASE_1_2

Clinical Trials (1)

NCT02706353APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

Publications: 12 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$16M0%

R&D Spend

$59M(364%)18%

Net Income

-$77M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

Cancer discovery

2026

PMID:42013310

Targeting the novel immune checkpoint KLRG1 is markedly therapeutic against cancer through multiple lymphocyte subsets.